Aligos Therapeutics, Inc. (ALGS)
NASDAQ: ALGS · IEX Real-Time Price · USD
0.504
+0.011 (2.17%)
At close: Jul 19, 2024, 4:00 PM
0.530
+0.026 (5.22%)
Pre-market: Jul 22, 2024, 9:12 AM EDT
Aligos Therapeutics Employees
Aligos Therapeutics had 66 employees as of December 31, 2023. The number of employees decreased by 17 or -20.48% compared to the previous year.
Employees
66
Change (1Y)
-17
Growth (1Y)
-20.48%
Revenue / Employee
$208,970
Profits / Employee
-$1,508,894
Market Cap
37.79M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 66 | -17 | -20.48% |
Dec 31, 2022 | 83 | -10 | -10.75% |
Dec 31, 2021 | 93 | 19 | 25.68% |
Dec 31, 2020 | 74 | 13 | 21.31% |
Dec 31, 2019 | 61 | - | - |
Related Stocks
Company Name | Employees |
---|---|
Concord Medical Services Holdings | 727 |
DarioHealth | 294 |
Precision Optics Corporation | 85 |
Xilio Therapeutics | 73 |
Cue Biopharma | 53 |
Curis | 49 |
IN8bio | 31 |
Ocean Biomedical | 9 |
ALGS News
- 32 minutes ago - Aligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd. - GlobeNewsWire
- 12 days ago - Aligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHB - GlobeNewsWire
- 6 weeks ago - Aligos Therapeutics Presents Positive Data at the EASL Congress 2024 - GlobeNewsWire
- 2 months ago - Aligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024 - GlobeNewsWire
- 2 months ago - Aligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASH - GlobeNewsWire
- 2 months ago - Aligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024 - GlobeNewsWire
- 3 months ago - Aligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 Study - GlobeNewsWire
- 4 months ago - Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies - GlobeNewsWire